215 related articles for article (PubMed ID: 37214450)
21. Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.
Inokuchi K; Mori H; Matsuzaki J; Hirata K; Harada Y; Saito Y; Suzuki H; Kanai T; Masaoka T
Helicobacter; 2022 Aug; 27(4):e12900. PubMed ID: 35644041
[TBL] [Abstract][Full Text] [Related]
22. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
[TBL] [Abstract][Full Text] [Related]
23. Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of
Sue S; Maeda S
Gut Liver; 2021 Nov; 15(6):799-810. PubMed ID: 33850058
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials.
Sun Y; Yue L; Hu W
Eur J Clin Pharmacol; 2023 Feb; 79(2):279-288. PubMed ID: 36527456
[TBL] [Abstract][Full Text] [Related]
25. Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of
Furuta T; Yamade M; Higuchi T; Takahashi S; Ishida N; Tani S; Tamura S; Iwaizumi M; Hamaya Y; Osawa S; Sugimoto K
J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176551
[TBL] [Abstract][Full Text] [Related]
26.
Sue S; Sasaki T; Kaneko H; Irie K; Kondo M; Maeda S
JGH Open; 2021 Feb; 5(2):307-311. PubMed ID: 33553672
[TBL] [Abstract][Full Text] [Related]
27. Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating
Hu Y; Xu X; Liu XS; He C; Ouyang YB; Li NS; Xie C; Peng C; Zhu ZH; Xie Y; Shu X; Zhu Y; Graham DY; Lu NH
Front Immunol; 2022; 13():1049908. PubMed ID: 36726990
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis.
Shinozaki S; Kobayashi Y; Osawa H; Sakamoto H; Hayashi Y; Lefor AK; Yamamoto H
Digestion; 2021; 102(3):319-325. PubMed ID: 31914442
[TBL] [Abstract][Full Text] [Related]
29. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line
Suzuki S; Gotoda T; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Ito H; Kawamura M; Ogata Y; Ohtaka M; Nakahara M; Kawabe K
Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of vonoprazan in quadruple therapy for
Zhuang X; Jiang H; Jin D; Sun M; Wang Z; Wang X
Gastroenterol Rep (Oxf); 2024; 12():goae036. PubMed ID: 38628396
[TBL] [Abstract][Full Text] [Related]
31. First-Line
Sue S; Suzuki N; Shibata W; Sasaki T; Yamada H; Kaneko H; Tamura T; Ishii T; Kondo M; Maeda S
Gastroenterol Res Pract; 2017; 2017():2019802. PubMed ID: 29181022
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
Bi H; Chen X; Chen Y; Zhao X; Wang S; Wang J; Lyu T; Han S; Lin T; Li M; Yuan D; Liu J; Shi Y
Chin Med J (Engl); 2022 Jul; 135(14):1707-1715. PubMed ID: 36193978
[TBL] [Abstract][Full Text] [Related]
33. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
Ang D; Koo SH; Chan YH; Tan TY; Soon GH; Tan CK; Lin KW; Krishnasamy-Balasubramanian JK; Wong YJ; Kumar R; R R; Tan Y; Ong PJ; Tan YJ; Li JW; Kwek AB; Ang TL
Aliment Pharmacol Ther; 2022 Aug; 56(3):436-449. PubMed ID: 35665947
[TBL] [Abstract][Full Text] [Related]
34. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
Saito Y; Serizawa H; Kato Y; Nakano M; Nakamura M; Saito H; Suzuki H; Kanai T
World J Gastroenterol; 2015 Dec; 21(48):13548-54. PubMed ID: 26730167
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China.
Zhou JJ; Shi X; Zheng SP; Tang D; Cai T; Yao Y; Wang F
Helicobacter; 2020 Dec; 25(6):e12755. PubMed ID: 32914914
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of vonoprazan-based regimen for Helicobacter pylori eradication therapy in Japanese adolescents: a prospective multicenter study.
Kakiuchi T; Matsuo M; Endo H; Sakata Y; Esaki M; Noda T; Imamura I; Hashiguchi K; Ogata S; Fujioka Y; Hanada K; Fukuda K; Yoshimura M; Kajiwara T; Yamamoto K; Yamaguchi D; Kawakubo H; Matsunaga T; Sumino M; Matsunaga K; Muro E; Watanabe A; Fujimoto K
J Gastroenterol; 2023 Mar; 58(3):196-204. PubMed ID: 36528706
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study.
Hirata Y; Yamada A; Niikura R; Shichijo S; Hayakawa Y; Koike K
Helicobacter; 2020 Oct; 25(5):e12719. PubMed ID: 32602161
[TBL] [Abstract][Full Text] [Related]
38. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
[TBL] [Abstract][Full Text] [Related]
40. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
